GSTP1, PRDX2 and NFE2L2: Potential Markers for Primary Stage Breast Cancer.

IF 3 4区医学 Q2 PHARMACOLOGY & PHARMACY

Current drug targets Pub Date : 2025-07-04 DOI:10.2174/0113894501393175250627013915

Syeda Abiha Zehra Jaffari, Fatima Haider, Nida Syed, Amber Ilyas, Farha Idrees, Alex von Kriegsheim, Roopesh Krishnankutty, Syeda Nuzhat Nawab, Zehra Hashim

{"title":"GSTP1, PRDX2 and NFE2L2: Potential Markers for Primary Stage Breast Cancer.","authors":"Syeda Abiha Zehra Jaffari, Fatima Haider, Nida Syed, Amber Ilyas, Farha Idrees, Alex von Kriegsheim, Roopesh Krishnankutty, Syeda Nuzhat Nawab, Zehra Hashim","doi":"10.2174/0113894501393175250627013915","DOIUrl":null,"url":null,"abstract":"Introduction: Breast cancer incidence and mortality have continued to rise over the past few decades. Despite advancements made in clinical research, the most imperative feature of breast cancer management is the diagnosis at the earliest stages. The current focus of the study is to identify and quantify differentially expressed oxidative stress-related proteins as putative early- stage markers for breast cancer.Methods: Normal and cancerous breast tissue samples (n = 40) were collected after approval from the institutional bioethics committee (IBC) with patient consent. A label-free proteomic approach was used to quantify oxidative stress-related proteins. Gene expression of GSTP1, PRDX2, HSP90, NFE2L2, and miR-365a was quantified using RT-qPCR in all samples. Protein expression of PRDX2 and GSTP1 was further analyzed using immunohistochemistry.Results: The protein and gene expression of PRDX2, GSTP1, and HSP90 were significantly upregulated (p < 0.05) in cancerous samples as compared to normal. However, gene and protein expression of the transcription factor NFE2L2 was significantly downregulated (p < 0.05) in diseased samples. OncomiR-365a was also significantly upregulated (p < 0.05) in cancerous samples. Immunohistochemical analysis also confirmed the upregulated expression of GSTP1 and PRDX2 in cancer tissues.Discussion: Our study provides insight into the significant role of GSTP1, PRDX2, and NFE2L2 in the pathophysiology of the disease as early-stage breast cancer markers. It is suggested that altered expression of these key proteins could play a protective role in reducing the damage.Conclusion: It can be concluded that GSTP1, PRDX2, and NFE2L2 may serve as predictive early- stage markers for diagnosis and potential therapeutic targets for breast cancer.","PeriodicalId":10805,"journal":{"name":"Current drug targets","volume":" ","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2025-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current drug targets","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0113894501393175250627013915","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Breast cancer incidence and mortality have continued to rise over the past few decades. Despite advancements made in clinical research, the most imperative feature of breast cancer management is the diagnosis at the earliest stages. The current focus of the study is to identify and quantify differentially expressed oxidative stress-related proteins as putative early- stage markers for breast cancer.

Methods: Normal and cancerous breast tissue samples (n = 40) were collected after approval from the institutional bioethics committee (IBC) with patient consent. A label-free proteomic approach was used to quantify oxidative stress-related proteins. Gene expression of GSTP1, PRDX2, HSP90, NFE2L2, and miR-365a was quantified using RT-qPCR in all samples. Protein expression of PRDX2 and GSTP1 was further analyzed using immunohistochemistry.

Results: The protein and gene expression of PRDX2, GSTP1, and HSP90 were significantly upregulated (p < 0.05) in cancerous samples as compared to normal. However, gene and protein expression of the transcription factor NFE2L2 was significantly downregulated (p < 0.05) in diseased samples. OncomiR-365a was also significantly upregulated (p < 0.05) in cancerous samples. Immunohistochemical analysis also confirmed the upregulated expression of GSTP1 and PRDX2 in cancer tissues.

Discussion: Our study provides insight into the significant role of GSTP1, PRDX2, and NFE2L2 in the pathophysiology of the disease as early-stage breast cancer markers. It is suggested that altered expression of these key proteins could play a protective role in reducing the damage.

Conclusion: It can be concluded that GSTP1, PRDX2, and NFE2L2 may serve as predictive early- stage markers for diagnosis and potential therapeutic targets for breast cancer.

查看原文本刊更多论文

GSTP1， PRDX2和NFE2L2：原发性乳腺癌的潜在标志物

导读：在过去的几十年里，乳腺癌的发病率和死亡率持续上升。尽管临床研究取得了进步，但乳腺癌治疗最重要的特点是在早期阶段进行诊断。目前研究的重点是确定和量化氧化应激相关蛋白的差异表达，作为乳腺癌的早期标志物。方法：经机构生物伦理委员会（IBC）批准并征得患者同意后，采集正常和癌性乳腺组织样本（n = 40）。采用无标记蛋白质组学方法定量氧化应激相关蛋白。采用RT-qPCR定量检测所有样品中GSTP1、PRDX2、HSP90、NFE2L2和miR-365a的基因表达。免疫组化分析PRDX2和GSTP1蛋白表达。结果：癌组织中PRDX2、GSTP1、HSP90蛋白及基因表达量较正常组织明显上调（p < 0.05）。而转录因子NFE2L2的基因和蛋白表达在患病样品中显著下调（p < 0.05）。癌样中OncomiR-365a也显著上调（p < 0.05）。免疫组化分析也证实GSTP1和PRDX2在癌组织中表达上调。讨论：我们的研究揭示了GSTP1、PRDX2和NFE2L2作为早期乳腺癌标志物在疾病病理生理中的重要作用。提示这些关键蛋白的表达改变可能在减少损伤中起保护作用。结论：GSTP1、PRDX2和NFE2L2可作为乳腺癌早期诊断的预测性标志物和潜在的治疗靶点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current drug targets 医学-药学

CiteScore

6.20

自引率

0.00%

发文量

127

审稿时长

3-8 weeks

期刊介绍： Current Drug Targets aims to cover the latest and most outstanding developments on the medicinal chemistry and pharmacology of molecular drug targets e.g. disease specific proteins, receptors, enzymes, genes. Current Drug Targets publishes guest edited thematic issues written by leaders in the field covering a range of current topics of drug targets. The journal also accepts for publication mini- & full-length review articles and drug clinical trial studies. As the discovery, identification, characterization and validation of novel human drug targets for drug discovery continues to grow; this journal is essential reading for all pharmaceutical scientists involved in drug discovery and development.